<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01103726</url>
  </required_header>
  <id_info>
    <org_study_id>A8241013</org_study_id>
    <nct_id>NCT01103726</nct_id>
  </id_info>
  <brief_title>Evaluation Of Striatal Glucose Metabolism With Positron Emission Tomography Following PF-02545920 In Healthy Subjects</brief_title>
  <official_title>Evaluation Of Regional Glucose Metabolism In Striatum As Measured By [18f]-Fluorodeoxyglucose Positron Emission Tomography Following Single Oral Dose Administration Of PF-02545920 In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that PF-02545920 will increase glucose metabolism in a part of the brain
      called the striatum.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose metabolic rates in striatum using standard Region of Interest (ROI) analysis method.</measure>
    <time_frame>Stage 1: Day 1, 8. Stage 2: Day 1, 8, 15.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Whole brain glucose metabolic rate.</measure>
    <time_frame>Stage 1: Day 1, 8. Stage 2: Day 1, 8, 15.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative glucose metabolic rate in striatum.</measure>
    <time_frame>Stage 1: Day 1, 8. Stage 2: Day 1, 8, 15.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose metabolic rate in striatal subregions: putamen and caudate nucleus.</measure>
    <time_frame>Stage 1: Day 1, 8. Stage 2: Day 1, 8, 15.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative glucose metabolic rate in striatal subregions: putamen and caudate nucleus.</measure>
    <time_frame>Stage 1: Day 1, 8. Stage 2: Day 1, 8, 15.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose metabolic rate in striatum determined using data-driven ROI analysis method.</measure>
    <time_frame>Stage 1: Day 1, 8. Stage 2: Day 1, 8, 15.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative glucose metabolic rate in striatum determined using data-driven ROI analysis method.</measure>
    <time_frame>Stage 1: Day 1, 8. Stage 2: Day 1, 8, 15.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect size comparison between standard ROI and data-driven ROI analysis methods using both regional glucose metabolic rate and relative regional glucose metabolic rate.</measure>
    <time_frame>Stage 1: Day 1, 8. Stage 2: Day 1, 8, 15.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Stage 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-02545920</intervention_name>
    <description>1 and 5 mg tablets, 6 mg single dose</description>
    <arm_group_label>Stage 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching placebo tablets, single dose</description>
    <arm_group_label>Stage 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-02545920</intervention_name>
    <description>1 mg tablets, 3 mg single dose</description>
    <arm_group_label>Stage 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-02545920</intervention_name>
    <description>5 mg tablets, 15 mg single dose</description>
    <arm_group_label>Stage 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching placebo tablets, single dose</description>
    <arm_group_label>Stage 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy right-handed male and female subjects between the ages of 18 and 55 years,
             inclusive

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs)

          -  An informed consent document signed and dated by the subject

          -  Subjects who are willing and able to comply with scheduled visits, treatment plan,
             laboratory tests, and other study procedures

        Exclusion Criteria:

          -  Women of reproductive potential

          -  History of agranulocytosis or movement disorder

          -  Positron Emission Tomography (PET) or Magnetic Resonance Imaging (MRI)
             contraindications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A8241013&amp;StudyName=Evaluation%20Of%20Striatal%20Glucose%20Metabolism%20With%20Positron%20Emission%20Tomography%20Following%20PF-02545920%20In%20Healthy%20Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2010</study_first_submitted>
  <study_first_submitted_qc>April 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2010</study_first_posted>
  <last_update_submitted>November 11, 2011</last_update_submitted>
  <last_update_submitted_qc>November 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FDG-PET</keyword>
  <keyword>regional cerebral glucose metabolism</keyword>
  <keyword>striatum</keyword>
  <keyword>PDE10 inhibitor</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

